Roche's Neuroscience Franchise Gets Lift From Huntington's Breakthrough

Roche is aiming to bolster its future neuroscience franchise with another potential breakthrough product in neurology to add to its clinical-stage efforts in Alzheimer's disease, and its success in developing the first therapy for primary progressive multiple sclerosis, Ocrevus.

Brain
Enlarged ventricles and nerve atrophy seen in Huntington's patients • Source: Shutterstock

More from Clinical Trials

More from R&D